Q-omics provides the consensus-scored H3P26 profile across patient tissues and cancer cell-line models. H3P26 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, H3P26 is differentially expressed in 3, with the highest sampling consensus in BLCA. Additionally, H3P26 RNA expression shows 5,636 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight PAAD, BLCA, and STAD as cancer lineages where H3P26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H3P26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H3P26 survival associations across molecular data types. H3P26 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H3P26 RNA expression–survival associations across cancer types. High H3P26 expression shows unfavorable associations in PAAD, UCEC, STAD, THCA and KIRC, but favorable associations in OV. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for H3P26 RNA expression.
This table summarizes H3P26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for H3P26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H3P26 shows lower tumor expression in KICH and higher tumor expression in BLCA and LUSC. The BLCA box plot shows higher H3P26 RNA expression in tumor versus normal tissue (log2 FC = +0.120, t-test p = .019).
This table shows molecular features associated with H3P26 in patient tissues and cancer cell lines. In patient samples, H3P26 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
